Valuation: Laboratorios Richmond S.A.C.I.F.

Market Cap 13TCr 8.44Cr 7.29Cr 6.85Cr 6.23Cr 12Cr 806.66Cr 12Cr 80Cr 31Cr 403.95Cr 32Cr 31Cr 1.34TCr P/E 2024
6.08x
P/E 2025 51.6x
Enterprise Value 36TCr 24Cr 21Cr 19Cr 18Cr 33Cr 2.29TCr 34Cr 227.83Cr 89Cr 1.15TCr 90Cr 88Cr 3.81TCr EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
06/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
11/05 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
07/05 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
07/03 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
06/11 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/25/09 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
06/24/06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
13/24/13 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
07/24/07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
11/24/11 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
1 day+0.32%
1 week+1.30%
Current month+0.32%
1 month-1.27%
3 months-2.51%
6 months-19.43%
Current year-21.27%
1 week 1,500
Extreme 1500
1,590
1 month 1,450
Extreme 1450
1,595
Current year 1,420
Extreme 1420
2,130
1 year 945
Extreme 945
2,300
3 years 480.5
Extreme 480.5
2,300
5 years 215
Extreme 215
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 29/04/2025
Corporate Officer/Principal - 29/04/2025
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.32%+1.30%+21.01%+162.67% 8.44Cr
-2.25%-0.47%+68.30%+116.05% 1,05200Cr
-0.66%+0.43%+47.39%+51.02% 63TCr
-0.54%+1.39%+20.69%+64.61% 44TCr
-1.99%-3.32%+38.71%+36.26% 35TCr
-1.05%-2.81%+23.07%+35.91% 29TCr
-2.12%-3.67%-1.14%+5.35% 24TCr
-0.63%+1.04%+40.05%+56.67% 22TCr
-1.19%-3.41%-9.57%-53.50% 20TCr
+0.16%+3.87%+16.89%+77.38% 17TCr
Average -0.99%+0.24%+26.54%+55.24% 35.95TCr
Weighted average by Cap. -1.36%+0.04%+39.09%+61.76%

Financials

2024 2025
Net sales 9.18TCr 6.17Cr 5.33Cr 5.01Cr 4.55Cr 8.56Cr 589.69Cr 8.7Cr 59Cr 23Cr 295.3Cr 23Cr 23Cr 981.32Cr 13TCr 8.51Cr 7.35Cr 6.91Cr 6.28Cr 12Cr 814.1Cr 12Cr 81Cr 32Cr 407.67Cr 32Cr 31Cr 1.35TCr
Net income 2.38TCr 1.6Cr 1.38Cr 1.3Cr 1.18Cr 2.22Cr 153.18Cr 2.26Cr 15Cr 5.96Cr 77Cr 6.01Cr 5.88Cr 254.91Cr 308.78Cr 20.74L 17.92L 16.84L 15.31L 28.79L 20Cr 29.26L 1.97Cr 77.13L 9.93Cr 77.89L 76.2L 33Cr
Net Debt 13TCr 8.98Cr 7.75Cr 7.29Cr 6.63Cr 12Cr 858.56Cr 13Cr 85Cr 33Cr 429.94Cr 34Cr 33Cr 1.43TCr 23TCr 16Cr 13Cr 13Cr 11Cr 22Cr 1.48TCr 22Cr 147.6Cr 58Cr 743.23Cr 58Cr 57Cr 2.47TCr
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
14/26/14 ARS 1,555.00 +0.32% 32,523
13/26/13 ARS 1,550.00 +0.98% 1,463
12/26/12 ARS 1,535.00 -2.54% 1,246
11/26/11 ARS 1,575.00 +1.29% 7,300
10/26/10 ARS 1,555.00 +1.30% 1,113
  1. Stock Market
  2. Stocks
  3. RICH Stock